 |
Background
Tuberculosis (TB) is an infectious disease caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs but can attack any part of the body such as the kidney, spine, and brain. When a person with TB in their lungs or throat coughs, laughs, sneezes, sings, or talks, the germs that cause TB may spread through the air. If another person breathes in these germs, there is a chance that he/she will become infected with TB.. Usually a person has to be close to someone with TB disease for a long period of time to become infected. If it is not treated, TB can be fatal, but it can almost always be treated and cured with the proper medications.
According to the World Health Organization, more than 2 billion people, equal to one-third of the world’s population, are infected with TB bacteria. 1 in 10 people infected with TB will become sick with active TB in their lifetime. 1.8 million people died from TB in 2008. TB is a disease of poverty affecting mostly young adults in their most productive years. The vast majority of TB deaths are in the developing world, and more than half of all deaths occur in Asia.
Below, we have provided information on tuberculosis, including clinical guidance, policies and directives, training material, and other resources, to assist healthcare providers and Service members and their families.
Table of Contents
Policies and Directives
DoD/Joint Forces
Army
Air Force
Navy / Marines
Clinical Guidance
- Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection, MMWR 60(48);1650-1653, 9 Dec 11
- Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection — United States, 2010, MMWR Vol 59 No RR-5, 25 Jun 10
- CDC Index of TB Guidelines
- Tuberculosis Coalition for Technical Assistance (TBCTA), International Standards for Tuberculosis Care, Mar 06
- Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis, Recommendations from the National Tuberculosis Controllers Association and CDC, MMWR 2005:RR 54 (No. RR-15)
- Controlling Tuberculosis in the United States, Recommendations from the American Thoracic Society, CDC and the Infectious Diseases Society of America, MMWR 2005;54 (No.RR 12)
- Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection - MMWR 2003; 52 (No. 31)
- CDC Recommendations and Reports, Treatment of Tuberculosis, 20 Jun 03
- CDC Recommendations and Reports, Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection, 9 Jun 00
- American Thoracic Society (ATS) Statements on Tuberculosis
Forms and Measures
- DA Form 5569, Isoniazid (INH) Clinic Flow Sheet, Feb 03
- DA Form 3897, Tuberculosis Registry, May 09
- NAVMED 6224/7, Initial Tuberculosis Exposure Risk Assessment, Aug 08
- NAVMED 6224/8, Interim Tuberculosis Exposure Risk Assessment, Jun 10
- NAVMED 6224/9, Monthly Evaluation for Patients Receiving Treatment for Latent Tuberculosis Infection (LTBI), Aug 08
- Forms and Measures
Fact Sheets
Other Related Information
Education and Training
Research
Related Links
|
 |